$CRIS
CURIS INC Stock $cris

$cris Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000119312514191561 Filed on May 09, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q1
Revenue	$4.801M	$1.285M	$871.4K
YoY Change	-11.16%	47.42%	-91.59%
Cost Of Revenue	$90.00K	$70.00K	$30.00K
YoY Change	125.0%	133.33%	-72.73%
Gross Profit	$4.710M	$1.220M	$840.0K
YoY Change	-12.13%	45.24%	-91.8%
Gross Profit Margin	98.1%	94.97%	96.39%
Selling, General & Admin	$2.930M	$2.830M	$2.570M
YoY Change	1.03%	10.12%	-8.21%
% of Gross Profit	62.21%	231.97%	305.95%
Research & Development	$3.329M	$3.146M	$2.628M
YoY Change	5.13%	19.69%	-49.84%
% of Gross Profit	70.68%	257.86%	312.91%
Depreciation & Amortization	$30.00K	$40.00K	$30.00K
YoY Change	-25.0%	33.33%	0.0%
% of Gross Profit	0.64%	3.28%	3.57%
Operating Expenses	$3.329M	$3.146M	$2.628M
YoY Change	5.13%	19.69%	-67.35%
Operating Profit	-$1.545M	-$4.753M	-$4.357M
YoY Change	118.75%	9.09%	-298.97%
Interest Expense	$949.7K	$951.0K	$947.8K
YoY Change	-0.84%	0.33%	3059.34%
% of Operating Profit
Other Income/Expense, Net	-$351.0K	-$810.6K	-$604.9K
YoY Change	-40.27%	34.0%
Pretax Income	-$1.900M	-$5.560M	-$4.960M
YoY Change	47.29%	12.1%	-322.42%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.896M	-$5.564M	-$4.962M
YoY Change	46.52%	12.12%	-322.95%
Net Earnings / Revenue	-39.48%	-433.11%	-569.44%
Basic Earnings Per Share
Diluted Earnings Per Share	-$110.5K	-$323.6K	-$309.6K
COMMON SHARES
Basic Shares Outstanding	85.95M shares	85.95M shares	80.10M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$55.80M	$57.80M	$50.50M
YoY Change	-2.28%	14.46%	12.22%
Cash & Equivalents	$10.16M	$7.908M	$9.719M
Short-Term Investments	$45.60M	$49.90M	$40.80M
Other Short-Term Assets	$400.0K	$500.0K	$400.0K
YoY Change	0.0%	25.0%	0.0%
Inventory
Prepaid Expenses
Receivables	$4.843M	$1.369M	$800.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$60.99M	$59.65M	$51.70M
YoY Change	4.39%	15.37%	13.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$439.4K	$408.6K	$400.0K
YoY Change	-12.28%	2.16%	0.0%
Goodwill	$8.982M	$8.982M
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments	$3.300M	$6.100M	$3.700M
YoY Change		64.86%
Other Assets	$78.31K	$91.17K	$300.0K
YoY Change	-39.66%	-69.61%	50.0%
Total Long-Term Assets	$12.91M	$15.72M	$13.40M
YoY Change	32.01%	17.28%	39.58%
TOTAL ASSETS
Total Short-Term Assets	$60.99M	$59.65M	$51.70M
Total Long-Term Assets	$12.91M	$15.72M	$13.40M
Total Assets	$73.90M	$75.36M	$65.10M
YoY Change	8.35%	15.77%	17.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.849M	$2.545M	$2.200M
YoY Change	10.51%	15.68%	-15.38%
Accrued Expenses	$1.510M	$1.246M	$1.200M
YoY Change	6.37%	3.85%	9.09%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.499M	$3.392M	$300.0K
YoY Change	302.06%	1030.81%
Total Short-Term Liabilities	$9.925M	$7.809M	$3.600M
YoY Change	85.0%	116.91%	-5.26%
LONG-TERM LIABILITIES
Long-Term Debt	$24.37M	$26.82M	$30.00M
YoY Change	-16.04%	-10.59%
Other Long-Term Liabilities	$191.1K	$194.7K	$1.200M
YoY Change	-4.03%	-83.77%	-70.0%
Total Long-Term Liabilities	$24.56M	$27.02M	$31.20M
YoY Change	-15.96%	-13.41%	680.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.925M	$7.809M	$3.600M
Total Long-Term Liabilities	$24.56M	$27.02M	$31.20M
Total Liabilities	$34.49M	$34.83M	$34.80M
YoY Change	-2.7%	0.08%	351.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$768.3M	-$766.4M
YoY Change	1.79%
Common Stock	$872.3K	$871.7K
YoY Change	5.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.524M	$1.524M
YoY Change	0.0%
Treasury Stock Shares	1.223M shares	1.223M shares
Shareholders Equity	$39.41M	$40.54M	$30.20M
YoY Change
Total Liabilities & Shareholders Equity	$73.90M	$75.36M	$65.10M
YoY Change	8.35%	15.77%	17.72%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$1.896M	-$5.564M	-$4.962M
YoY Change	46.52%	12.12%	-322.95%
Depreciation, Depletion And Amortization	$30.00K	$40.00K	$30.00K
YoY Change	-25.0%	33.33%	0.0%
Cash From Operating Activities	-$4.730M	-$5.310M	-$4.330M
YoY Change	-15866.67%	22.63%	-209.9%
INVESTING ACTIVITIES
Capital Expenditures	-$60.00K		$34.96K
YoY Change			-449.57%
Acquisitions
YoY Change
Other Investing Activities	$6.960M	$3.440M	$1.300M
YoY Change	-340.83%	164.62%	-117.02%
Cash From Investing Activities	$6.900M	$3.440M	$1.260M
YoY Change	-338.75%	173.02%	-116.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$180.4K	$297.7K
YoY Change		-39.39%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	80.00K	180.0K	40.00K
YoY Change	-97.23%	350.0%	-98.78%
NET CHANGE
Cash From Operating Activities	-4.730M	-5.310M	-4.330M
Cash From Investing Activities	6.900M	3.440M	1.260M
Cash From Financing Activities	80.00K	180.0K	40.00K
Net Change In Cash	2.250M	-1.690M	-3.030M
YoY Change	7400.0%	-44.22%	604.65%
FREE CASH FLOW
Cash From Operating Activities	-$4.730M	-$5.310M	-$4.330M
Capital Expenditures	-$60.00K		$34.96K
Free Cash Flow	-$4.670M	-$5.310M	-$4.365M
YoY Change	-15666.67%	21.65%	-210.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	cris	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	9046
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.019	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.70	pure
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	85948078	shares
CY2013Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1186919
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9718974
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	85948078	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1373517	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87170924	shares
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2014Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	1222846	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	3.55
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1246175
CY2014Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	26914398
CY2014Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	26822670
CY2014Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	635592
CY2014Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	207022
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	807583325
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2545041
CY2014Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	148825
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7808814
CY2014Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2750
CY2014Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	194731
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	40537758
CY2014Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	625163
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-766390497
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	871709
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	75363973
CY2013Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	11372493
CY2014Q1	us-gaap	Liabilities Fair Value Disclosure Nonrecurring LiabilitiesFairValueDisclosureNonrecurring	0
CY2014Q1	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	139647
CY2014Q1	us-gaap	Liabilities Liabilities	34826215
CY2014Q1	us-gaap	Interest Payable Current InterestPayableCurrent	254736
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	3392435
CY2014Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	49855949
CY2014Q1	us-gaap	Long Term Investments LongTermInvestments	6081247
CY2014Q1	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	13877
CY2014Q1	us-gaap	Assets Current AssetsCurrent	59648307
CY2014Q1	us-gaap	Goodwill Goodwill	8982000
CY2014Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	48856394
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	91173
CY2014Q1	us-gaap	Assets Assets	75363973
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7907869
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1368920
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5800000
CY2014Q1	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	152610
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	501692
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5907000
CY2014Q1	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	1002402
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	6519000
CY2014Q1	us-gaap	Assets Fair Value Disclosure Nonrecurring AssetsFairValueDisclosureNonrecurring	0
CY2014Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	48853547
CY2014Q1	us-gaap	Treasury Stock Value TreasuryStockValue	1524029
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	408636
CY2014Q1	cris	Debt Instrument Current Carrying Amount DebtInstrumentCurrentCarryingAmount	3445951
CY2014Q1	cris	Warrant Liability Current WarrantLiabilityCurrent	625163
CY2014Q1	cris	Stock Issued During Period Due To Exercise Of Warrants StockIssuedDuringPeriodDueToExerciseOfWarrants	238805	shares
CY2014Q1	cris	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	12700
CY2014Q1	cris	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	9853
CY2010Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1612322	shares
CY2010Q1	cris	Registered Direct Offering Number Of Common Stock Per Unit RegisteredDirectOfferingNumberOfCommonStockPerUnit	1
CY2010Q1	cris	Registered Direct Offering Units RegisteredDirectOfferingUnits	6449288	shares
CY2010Q1	cris	Registered Direct Offering Number Of Warrant Per Unit RegisteredDirectOfferingNumberOfWarrantPerUnit	1
CY2010Q1	cris	Direct Offering Purchase Price DirectOfferingPurchasePrice	2.52
CY2012Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1488179
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12747709
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	85859016	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87081862	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1222846	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1911479
CY2013Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	28050291
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	27945186
CY2013Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1267954
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	178390
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	806660340
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2036864
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	166200
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6558517
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6984
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	196734
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	45173585
CY2013Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	716786
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-760826561
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	870819
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	80590808
CY2013Q4	us-gaap	Liabilities Liabilities	35417223
CY2013Q4	us-gaap	Interest Payable Current InterestPayableCurrent	298935
CY2013Q4	us-gaap	Liabilities Fair Value Disclosure Nonrecurring LiabilitiesFairValueDisclosureNonrecurring	0
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2610174
CY2013Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	48588135
CY2013Q4	us-gaap	Long Term Investments LongTermInvestments	10726685
CY2013Q4	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	13877
CY2013Q4	us-gaap	Assets Current AssetsCurrent	60165947
CY2013Q4	us-gaap	Goodwill Goodwill	8982000
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	47592763
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	104034
CY2013Q4	us-gaap	Assets Assets	80590808
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9591487
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1477188
CY2013Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	152496
CY2013Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	166487
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	495260
CY2013Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	1001802
CY2013Q4	us-gaap	Assets Fair Value Disclosure Nonrecurring AssetsFairValueDisclosureNonrecurring	0
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	47586333
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1524029
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	445655
CY2013Q4	cris	Debt Instrument Current Carrying Amount DebtInstrumentCurrentCarryingAmount	2663677
CY2013Q4	cris	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	15476
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	640000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.09
CY2010Q1	cris	Proceeds From Registered Direct Offering Of Common Stock And Warrants Net Of Issuance Costs ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts	14942000
CY2013	cris	Available For Sale Securities Weighted Average Maturity AvailableForSaleSecuritiesWeightedAverageMaturity	P4M21D
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	80096650	shares
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4328086
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.14
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13123460	shares
CY2013Q1	us-gaap	Revenues Revenues	871435
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	19948
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4963351
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1286000
CY2013Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	10088329
CY2013Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	261475
CY2013Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	41612
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4357364
CY2013Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	301260
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-143635
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-604930
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-4962294
CY2013Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-197938
CY2013Q1	us-gaap	Royalty Revenue RoyaltyRevenue	664400
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	34957
CY2013Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-13918
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-442908
CY2013Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-301260
CY2013Q1	us-gaap	Costs And Expenses CostsAndExpenses	5228799
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2567122
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	36226
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	170000
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	660566
CY2013Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	34158
CY2013Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	634208
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3028735
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	1263125
CY2013Q1	us-gaap	Interest Expense InterestExpense	947802
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	297701
CY2013Q1	us-gaap	Royalty Expense RoyaltyExpense	33220
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2628457
CY2013Q1	us-gaap	Interest Costs Incurred Capitalized InterestCostsIncurredCapitalized	335832
CY2013Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	26195
CY2014Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	13388600
CY2014Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	353619
CY2013Q1	cris	Research And Development Revenue ResearchAndDevelopmentRevenue	207035
CY2013Q1	cris	Adjustments To Additional Paid In Capital Share Based Compensation Mark To Market On Stock Options To Non Employees AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationMarkToMarketOnStockOptionsToNonEmployees	16240
CY2014Q1	dei	Trading Symbol TradingSymbol	CRIS
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	CURIS INC
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001108205
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-91623
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.71	pure
CY2014Q1	us-gaap	Nature Of Operations NatureOfOperations	<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left"><b>1.</b></td> <td style="FONT-SIZE: 8pt" valign="top" width="1%"> </td> <td valign="top" align="left"><b><u>Nature of Business</u></b></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Curis, Inc. is an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers. As used throughout these consolidated financial statements, the term “the Company” refers to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term “Curis” refers to Curis, Inc.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company conducts its research and development programs both internally and through strategic collaborations. The Company is leveraging its experience in targeting signaling pathways in seeking to develop drug candidates including CUDC-907, a dual histone deacetylase, or HDAC and phosphoinostide-3 kinase, or PI3K, inhibitor, and CUDC-427, a small molecule antagonist of the inhibitor of apoptosis, or IAP, proteins. Erivedge<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">®</sup>, the first and only approved medicine for the treatment of advanced basal cell carcinoma, or BCC, is being commercialized by F. Hoffmann-La Roche Ltd., or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. The Company’s licensee Debiopharm is advancing the clinical development of the heat shock protein 90, or HSP90, inhibitor, Debio 0932.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The Company expects that any products that are successfully developed and commercialized would be used in the health care industry and would be regulated in the United States by the Food and Drug Administration, or FDA, and in overseas markets by similar regulatory authorities.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company is subject to risks common to companies in the biotechnology industry as well as risk factors that are specific to the Company’s business, including, but not limited to: the Company’s reliance on Genentech and Roche to successfully commercialize Erivedge; the Company’s ability to advance and expand its research and development programs; the Company’s ability to obtain adequate financing to fund its operations; the ability of the Company’s wholly owned subsidiary, Curis Royalty, LLC, or Curis Royalty, to satisfy the terms of its loan agreement with BioPharma Secured Debt Fund II Sub, S.à r.l., a Luxembourg limited liability company managed by Pharmakon Advisors, or BioPharma-II; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; dependence on key personnel; the Company’s ability to comply with regulatory requirements; and the Company’s ability to execute on its overall business strategies.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company’s future operating results will largely depend on the magnitude of payments from its current and potential future corporate collaborators and the progress of drug candidates currently in its development pipeline. The results of the Company’s operations will vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: Roche and Genentech’s ability to successfully commercialize Erivedge; positive results in Genentech’s ongoing clinical trials; the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidates; and the Company’s ability to successfully enter into one or more material licenses or collaboration agreements for its proprietary drug candidates.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company anticipates that existing cash, cash equivalents and investments at March 31, 2014 should enable it to maintain current and planned operations into 2016. The Company’s ability to continue funding its planned operations beyond this period is dependent upon, among other things, the success of its collaborations with Genentech, Debiopharm and the Leukemia & Lymphoma Society, or LLS, including its receipt of additional contingent cash payments under these collaborations; its ability to control expenses and its ability to raise additional funds through equity or debt financings, new collaborations or other sources of financing. The Company may not be able to successfully raise additional funds or enter into or continue any corporate collaborations and the timing, amount and likelihood of the Company receiving payments under such collaborations is highly uncertain. If the Company is unable to obtain adequate financing, the Company may be required to reduce or delay spending on its research and/or development programs.</p> </div>
CY2014Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	48760
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4753343
CY2014Q1	us-gaap	Costs And Expenses CostsAndExpenses	6037976
CY2014Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	1322582
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-159130
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P60D
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85917592	shares
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5305886
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.97
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2014Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	Segment
CY2014Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12706573	shares
CY2014Q1	us-gaap	Revenues Revenues	1284633
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6420
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5559702
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	0
CY2014Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	91623
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-108268
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-810593
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-5563936
CY2014Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	46102
CY2014Q1	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	968963
CY2014Q1	us-gaap	Royalty Revenue RoyaltyRevenue	1288248
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment
CY2014Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-13877
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2826898
CY2014Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	-353619
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	180431
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	88000
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	743444
CY2014Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	37019
CY2014Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	258050
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1683618
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	3441837
CY2014Q1	us-gaap	Interest Expense InterestExpense	950976
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	180431
CY2014Q1	us-gaap	Royalty Expense RoyaltyExpense	65148
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3145930
CY2014Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	26213
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	48011
CY2014Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	16816560
CY2014Q1	cris	Share Based Compensation Plans ShareBasedCompensationPlans	2	Plans
CY2014Q1	cris	Available For Sale Securities Weighted Average Maturity AvailableForSaleSecuritiesWeightedAverageMaturity	P5Y3M18D
CY2014Q1	cris	Debt Issuance Costs Gross DebtIssuanceCostsGross	421715
CY2014Q1	cris	Share Based Compensation Arrangement By Share Based Payment Award Options Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssued	640000	shares
CY2014Q1	cris	Research And Development Revenue ResearchAndDevelopmentRevenue	-3615
CY2014Q1	cris	Class Of Warrant Or Right Expiration Year And Month ClassOfWarrantOrRightExpirationYearAndMonth	2015-01
CY2014Q1	cris	Adjustments To Additional Paid In Capital Share Based Compensation Mark To Market On Stock Options To Non Employees AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationMarkToMarketOnStockOptionsToNonEmployees	55672

Files In Submission

Name	View Source	Status
0001193125-14-191561-index-headers.html	Edgar Link	pending
0001193125-14-191561-index.html	Edgar Link	pending
0001193125-14-191561.txt	Edgar Link	pending
0001193125-14-191561-xbrl.zip	Edgar Link	pending
cris-20140331.xml	Edgar Link	completed
cris-20140331.xsd	Edgar Link	pending
cris-20140331_cal.xml	Edgar Link	unprocessable
cris-20140331_def.xml	Edgar Link	unprocessable
cris-20140331_lab.xml	Edgar Link	unprocessable
cris-20140331_pre.xml	Edgar Link	unprocessable
d706926d10q.htm	Edgar Link	pending
d706926dex101.htm	Edgar Link	pending
d706926dex311.htm	Edgar Link	pending
d706926dex312.htm	Edgar Link	pending
d706926dex321.htm	Edgar Link	pending
d706926dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRIS
CURIS INC Stock $cris

2014 Q2 Form 10-Q Financial Statement

#000119312514191561 Filed on May 09, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS CURIS INC Stock $cris

2014 Q2 Form 10-Q Financial Statement

#000119312514191561 Filed on May 09, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS
CURIS INC Stock $cris